Patents Assigned to Neovacs S.A.
  • Patent number: 7208148
    Abstract: The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a method for preparing, use of the resulting product in a method of treatment for the human or animal body, a pharmaceutical composition and a vaccine containing as active principle, at least one of the carboxymethylated proteins or fragments.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: April 24, 2007
    Assignee: Neovacs S.A.
    Inventors: Daniel Zagury, Jean-François Zagury
  • Patent number: 7067246
    Abstract: The serum levels of anti-tat antibodies, tat protein, and p24 protein are predictive of disease progression in HIV infected individuals and serve as prognostic markers. The present invention relates to a method for determining the prognosis of an HIV infected individual by measuring serum levels of one or more of these prognostic markers. In addition, a method for monitoring whether an HIV infected individual is in need of immunization with a tat vaccine and a method for monitoring the efficacy of immunization with a tat vaccine are also disclosed.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: June 27, 2006
    Assignee: Neovacs S.A.
    Inventors: Daniel Zagury, Jean-Francois Zagury